| Autor: |
Chen W; School of Pharmacy, Quanzhou Medical College, Quanzhou 362011, Fujian, China., Xian N; Institute of Immunotherapy, Fujian Medical University, Fuzhou 350122, Fujian, China., Lin S; School of Pharmacy, Quanzhou Medical College, Quanzhou 362011, Fujian, China., Liao W; School of Pharmacy, Quanzhou Medical College, Quanzhou 362011, Fujian, China., Chen M; School of Pharmacy, Quanzhou Medical College, Quanzhou 362011, Fujian, China. |
| Abstrakt: |
The aim of this study was to investigate the functional characteristics and in vitro specific killing effect of EGFRvIII CAR-T cells co-expressing interleukin-15 and chemokine CCL19, in order to optimize the multiple functions of CAR-T cells and improve the therapeutic effect of CAR-T cells targeting EGFRvIII on glioblastoma (GBM). The recombinant lentivirus plasmid was obtained by genetic engineering, transfected into 293T cells to obtain lentivirus and infected T cells to obtain the fourth generation CAR-T cells targeting EGFRvIII (EGFRvIII-IL-15-CCL19 CAR-T). The expression rate of CAR molecules, proliferation, chemotactic ability, in vitro specific killing ability and anti-apoptotic ability of the fourth and second generation CAR-T cells (EGFRvIII CAR-T) were detected by flow cytometry, cell counter, chemotaxis chamber and apoptosis kit. The results showed that compared with EGFRvIII CAR-T cells, EGFRvIII-IL-15-CCL19 CAR-T cells successfully secreted IL-15 and CCL19, and had stronger proliferation, chemotactic ability and anti-apoptosis ability in vitro (all P < 0.05), while there was no significant difference in killing ability in vitro . Therefore, CAR-T cells targeting EGFRvIII and secreting IL-15 and CCL19 are expected to improve the therapeutic effect of glioblastoma and provide an experimental basis for clinical trials. |
